Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A-SAB - Alectinib Followed by Concomitant Consolidation SBRT/Hypofractionated Radiation Therapy/SRS in Advanced NSCLC With ALK-rearrangement

NCT05724004 is registered in ClinicalTrials.gov with Karolinska University Hospital as lead sponsor.

NCT NCT05724004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05724004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A-SAB - Alectinib Followed by Concomitant Consolidation SBRT/Hypofractionated Radiation Therapy/SRS in Advanced NSCLC With ALK-rearrangement
Lead sponsor
Karolinska University Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
October 5, 2023
Completion date
June 20, 2031
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene mutation, non-small cell lung cancer, radiotherapy side effect